A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysisMatthew Krebs,Paal Brunsvig,Aslaug Helland,Nuria Vinolas Segarra,Santiago Ponce Aix,Enric Carcereny Costa,Manuel Domine Gomez,Jose Manuel Trigo Perez,Edurne Arriola,Rosario Garcia Campelo,James Spicer,Jonathan Thompson,Ana Laura Ortega Granados,Robert Holt,James Lorens,Muhammad Shoaib,Abdul Siddiqui,Emmett Schmidt,Michael Chisamore,Enriqueta FelipJOURNAL FOR IMMUNOTHERAPY OF CANCER（2019）引用 14|浏览25暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
